TITLE

Clinical pharmacokinetics: brief reports

PUB. DATE
April 2006
SOURCE
Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely coadministered in diabetic patients, have a narrow efficacy/toxicity ratio or are known to induce or inhibit the cytochrome P450 system) may have important clinical implications. As metformin is not metabolised and does not inhibit the metabolism of other drugs, there are no clinically relevant metabolic interactions with this agent. However, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver and may be subject to drug-drug metabolic interactions, resulting in either hypoglycaemia or worsening of metabolic control
ACCESSION #
20254476

 

Related Articles

  • Effects of drug-drug interactions involving oral antihyperglycaemics are, with the exception of hypoglycaemia, mostly clinically unimportant.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p18 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • First reports of serious adverse drug reactions in recent weeks.  // Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16 

    Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely...

  • The Effectiveness of Metformin versus Glyburide in Type 2 Diabetes: Results from ADOPT (A Diabetes Outcomes Progression Trial). Herman, William H.; Haffner, Steven M.; Kahn, Steven E.; Zinman, Bernard; Holman, Rury R.; Viberti, Giancarlo F.; Lachin, John M.; Kravitz, Barbara G.; Heise, Mark A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA146 

    ADOPT compared initial oral monotherapies in recently diagnosed type 2 diabetic patients and found rosiglitazone to be superior to metformin (Met) and glyburide (Gly) as assessed by time to monotherapy failure (MF), defined as time to the first of two successive fasting plasma glucose (FPG)...

  • Pramlintide Improved Glycemic Control and Reduced Body Weight in Patients With Type 2 Diabetes Treated With Basal Insulin (Without Mealtime Insulin) and a Thiazolidinedione. Lorenzi, Gayle; Frias, Juan; Lutz, Karen; Kesty, Nicole; Zhang, Bei; Kolterman, Orville // Diabetes;Jun2007 Supplement 1, Vol. 56, pA147 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, improves glycemic control and body weight in patients with type 2 diabetes (T2DM) treated with insulin with or without sulfonylurea (SFU) and/or metformin (MET). Its efficacy and safety as an adjunct to insulin+thiazolidinedione...

  • Repaglinide and gemfibrozil: hazardous interaction.  // WHO Drug Information;2003, Vol. 17 Issue 2, p105 

    Reports that the European Agency for the Evaluation of Medicinal Products has issued a public statement concerning an interaction between repaglinide, a medicine used to lower blood sugar in diabetic patients, and gemfibrozil, a lipid-lowering agent. Indication that the blood glucose-lowering...

  • chlorpropamide.  // Royal Society of Medicine: Medicines;2002, p152 

    The article provides information on the drug chlorpropamide. It is a sulphonylurea which is used in diabetic treatment of Type II diabetes mellitus. It works by augmenting what remains of production in the pancreas and its effect lasts longer than that of most similar drugs. Unusually for a...

  • tolbutamide. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p749 

    An encyclopedia entry for "tolbutamide," which refers to an oral hypoglycaemic drug used for treating type 2 diabetes mellitus, is presented.

  • Treatment of type II diabetes. Nattrass, Malcolm // British Medical Journal (Clinical Research Edition);4/19/1986, Vol. 292 Issue 6527, p1033 

    Focuses on the clinical management of type II diabetes. Mechanism of action of sulphonylureas; Shift from long to a short acting drug among older patients; Control of hypoglycemia by administering oral hypoglycemic agents.

  • Improvements in Cardiovascular Risk Factors Accompanied Improved Glycemic Control and Weight Reduction in Patients With Type 2 Diabetes Treated With Exenatide for 3.5y. Kendall, David; Blonde, Lawrence; Mac, Susanna; Xuesong Guan; Holcombe, John; Okerson, Ted; Kim, Dennis; Bhole, Deepak // Diabetes;Jun2007 Supplement 1, Vol. 56, pA149 

    The article focuses on a study on the improvements in cardiovascular risk factors, glycemic control and weight reduction in type 2 diabetes patients treated with exenatide in 3.5 years conducted in the U.S. It cites that treatment with exenatide in type 2 diabetics has been associated with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics